Dr. Peter A. Bercz, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,140
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME113259 · PA license MD432552 -
Critical Care Medicine (Internal Medicine) Physician
FL license ME113259 · PA license MD432552
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sacred Heart Hospital Pensacola, FL
- Baptist Hospital Pensacola, FL
- Gulf Breeze Hospital Gulf Breeze, FL
- Sacred Heart Hospital on The Emerald Coast Miramar Beach, FL
Medical groups
- Pensacola Lung Group, M.d.'s, P.a. (31 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,140
- Services billed
- 3,638
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 797 | 293 |
| Critical care, first 30-74 minutes | 421 | 213 |
| Established patient office or other outpatient visit, 30-39 minutes | 342 | 261 |
| Established patient office or other outpatient visit, 40-54 minutes | 314 | 235 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 254 | 140 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 136 | 128 |
| Test to examine how well the lungs exchange gases | 107 | 103 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 106 | 102 |
| Test to determine lung volumes using sensors | 65 | 62 |
| New patient office or other outpatient visit, 60-74 minutes | 60 | 60 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Pensacola, FL | 116 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Pensacola, FL | 102 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Pensacola, FL | 66 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Pensacola, FL | 60 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Pensacola, FL | 51 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Pensacola, FL | 50 |
| Montelukast Sodium Other prescribers in Pensacola, FL | 49 |
| Prednisone Other prescribers in Pensacola, FL | 40 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Pensacola, FL | 36 |
| Advair Hfa (fluticasone propion/salmeterol) Other prescribers in Pensacola, FL | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 75 payments worth $1,843 in total to this clinician.
| Intuitive Surgical, Inc. | $263 |
|---|---|
| GlaxoSmithKline, LLC. | $228 |
| Inspire Medical Systems, Inc. | $169 |
| AstraZeneca Pharmaceuticals LP | $156 |
| Insmed, Inc. | $146 |
| Genzyme Corporation | $134 |
| Avadel Cns Pharmaceuticals, LLC | $121 |
| Electromed, Inc. | $103 |
| Food and Beverage | $1,764 |
|---|---|
| Education | $78.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi-aventis U.S. LLC Dec 4, 2025 | Education DUPIXENT · Immunology · in-kind | $78.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $500,569 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
Sanofi US Services Inc. · Completed · NCT06280391 - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983 - A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obs…
AstraZeneca Pharmaceuticals LP - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi US Services Inc. · Recruiting · NCT07190209
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.